Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : FB825
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Leo Pharma
Deal Size : $570.0 million
Deal Type : Licensing Agreement
LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825
Details : Oneness will be responsible for executing the Phase 2a study for Atopic Dermatitis in the United States and Microbio Shanghai will execute the Phase 2a study for allergic asthma in China.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : $40.0 million
April 15, 2020
Lead Product(s) : FB825
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Leo Pharma
Deal Size : $570.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?